Go Deep
Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,367 | -0.2 | 1.11 | 0.11 | 205.53 |
| Oct 2026 | 24,393 | -0.2 | 1.07 | 0.11 | 197.95 |
| Oct 2026 | 22,628 | -0.1 | 1.01 | 0.11 | 187.74 |
| Oct 2026 | 22,544 | -0.2 | 1.14 | 0.11 | 212.39 |
| Oct 2026 | 22,586 | -0.2 | 1.08 | 0.11 | 199.57 |
| Oct 2026 | 22,598 | -0.2 | 1.06 | 0.11 | 195.86 |
Ernexa Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -4,009,000.0 | -5,506,000.0 | -1,502,000.0 | -1,240,000.0 |
| EPS | -3.4 | -7.0 | — | -3.8 |
Ernexa Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 582,000.0 | 68,000.0 | 0.0 | — |
| Net Profit | -14,084,000.0 | -44,539,000.0 | -21,668,000.0 | -24,579,000.0 | — |
| EPS | -56.0 | -1,224.0 | -1,530.0 | -3,022.5 | — |
Ernexa Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 5,834,000.0 | 5,269,000.0 | 49,132,000.0 | 22,279,000.0 | — |
| Total Liabilities | 3,433,000.0 | 3,568,000.0 | 46,899,000.0 | 10,172,000.0 | — |
| Total Equity | 2,401,000.0 | 1,701,000.0 | 2,233,000.0 | 12,107,000.0 | — |
Owes vs Owns
Ernexa Therapeutics Inc. owed $0.49 for every $1 it owned in Jun 2026, up from $0.46 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.49× | 0.59× | 0.68× | 0.95× | 0.46× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ernexa Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 32.3%Receivables 14.5%Fixed assets (tangible) 9.4%Intangible assets 35.0%Other assets 8.8%
How it's funded — Dec 2025
Short-term debt 3.7%Long-term debt 4.7%Payables 19.3%Other liabilities 31.2%Shareholders' equity 41.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1.9 | 1.7 | 7.6 | 11.4 |
| Receivables | 0.8 | 0.4 | 0.4 | 1.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.5 | 0.8 | 33.3 | 1.3 |
| Intangible assets | 2.0 | 2.0 | 2.0 | 2.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.1 |
| Other assets | 0.5 | 0.3 | 5.8 | 6.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.2 | 2.2 | 1.8 |
| Long-term debt | 0.3 | 0.5 | 6.8 | 1.2 |
| Payables | 1.1 | 1.7 | 1.1 | 1.6 |
| Other liabilities | 1.8 | 1.2 | 36.8 | 5.6 |
| Shareholders' equity | 2.4 | 1.7 | 2.2 | 12.1 |
| Net tangible assets | 0.4 | -0.3 | 0.2 | 10.1 |
Ernexa Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -7,017,000.0 | -15,836,000.0 | -20,408,000.0 | -20,976,000.0 | — |
| Investing Activities | -37,000.0 | -365,000.0 | -19,000.0 | -47,000.0 | — |
| Financing Activities | 7,209,000.0 | 6,260,000.0 | 16,556,000.0 | 19,579,000.0 | — |